Penn's Abramson Cancer Center part of major phase III study for myeloma

Researchers from the Abramson Cancer Center of the University of Pennsylvania announced that findings from two large, international clinical trials show unprecedented survival for patients with multiple myeloma, a cancer that occurs in the blood-making cells of bone marrow. The findings show that with the oral drug lenalidomide (REVLIMID®), in combination with the steroid dexamethasone, patients significantly improved by all measures where previous treatments had failed – including a median survival of nearly three years – the longest median survival known for this difficult to treat patient group. Edward A. Stadtmauer, MD, Director of the Abramson Cancer Center Bone Marrow and Stem Cell...

Want to see the full article?

• Purchase this article for only $3.00